| Ytd | 179.59% | |
| 1y | 191.49% |
| Open | 2.79 | Prev Close | 2.76 | Low | 2.69 | High | 2.79 | Mkt Cap | 319.37M |
| Vol | 0.00 | Avg Vol | 3.84M | EPS | -1.09 | P/E | -2.51 | Forward P/E | -0.99 |
| Beta | 1.88 | Short Ratio | 3.10 | Inst. Own | 102.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.48 | 200-d Avg | 1.60 | 1yr Est | 6.31 |
FATE News
Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before reces
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag
US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Mul
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta
Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on F
SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag
FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemothera
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensu
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refracto
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supp
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly ear
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
During Thursday's session, 92 stocks hit new 52-week lows.
During Wednesday's trading, 103 companies set new 52-week lows.
On Tuesday, 46 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for
Friday's session saw 75 companies set new 52-week lows.
On Tuesday, 298 companies achieved new lows for the year.
During Friday's trading, 293 companies set new 52-week lows.
On Thursday, 241 companies hit new 52-week lows.
Monday saw 196 companies set new 52-week lows.
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin
Gainers
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
On Friday, 1043 companies hit new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to repo